Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID ...
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2™ insulin pump with Control-IQ+ ...
The t:slim X2 automated insulin delivery system with Control IQ+ technology. [Image courtesy of Tandem Diabetes Care] Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received approval to ...
This sub-analysis is the first study to evaluate AID outcomes for people with type 2 diabetes using the Center for Medicare and Medicaid Services (CMS) criteria for insulin pump coverage. Of the 319 ...
Insulin Syringe, ½mL Lo-Dose, Permanently Attached Needle, 28 G x ½", Blister Pkg, U-100 Micro-Fine IV, Orange, 100/bx, 5 bx/cs Insulin Syringe, ½mL Lo-Dose, Permanently Attached Needle, 28 G x ½", ...
The following is a summary of “Clinical Outcomes of Switching U-100 Intermediate or Basal Insulin to U-200 Insulin Degludec or U-300 Insulin Glargine,” published in the March 2025 issue of Journal of ...
Over 13 weeks, adults with type 2 diabetes using an automated insulin delivery (AID) system had a 0.6-percentage point greater drop in HbA1c than controls. The AID group also spent 3.4 more hours per ...
– Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults with type 2 diabetes – Control-IQ+ automated insulin delivery technology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback